Följ Umeå Biotech Incubator

Pressmeddelanden Visa alla 34 träffar

Umeåforskare vill rädda miljontals liv årligen – med ny antibiotika

Umeåforskare vill rädda miljontals liv årligen – med ny antibiotika

Pressmeddelanden   •   Nov 20, 2020 10:37 CET

18–24 november ordnas Antibiotic Awareness Week, för att uppmärksamma det stora problemet med antibiotikaresistens. Fredrik Almqvist på QureTech Bio är en av forskarna som försöker hitta en lösning. – Det här är ett lika stort problem som klimathotet. Vi måste hitta nya sätt att slå ut sjukdomsframkallande bakterier, på så vis kan vi rädda miljontals liv varje år, säger han.

QureTech Bio secures SEK 14 million investment - a very important milestone in their fight against antibiotic resistance

QureTech Bio secures SEK 14 million investment - a very important milestone in their fight against antibiotic resistance

Pressmeddelanden   •   Okt 26, 2020 14:07 CET

Venture capital company Nascent Invest has bought shares in Umeå-based QureTech Bio as part of a targeted new share issue. The multi-million SEK investment will provide long-term security for the Swedish life science company as it continues its work to discover and develop new solutions to combat antibiotic-resistant bacteria.

Diamyd Medical moves pharmaceutical production from USA to Umeå – hires

Diamyd Medical moves pharmaceutical production from USA to Umeå – hires

Pressmeddelanden   •   Okt 12, 2020 08:30 CEST

A recruitment drive is underway at Diamyd Medical's new vaccine facility in Umeå after the company announced it is moving production of the GAD65 protein, the active substance in the diabetes vaccine Diamyd, from abroad to Sweden. “This move gives us greater control and more knowledge about our study drug”, says Maja Johansson, Site Manager in Umeå.

New US agreement proclaimed "significant milestone” for Swedish biotech company

New US agreement proclaimed "significant milestone” for Swedish biotech company

Pressmeddelanden   •   Okt 09, 2020 08:30 CEST

Swedish Inficure Bio has signed an agreement with a publicly listed US biopharmaceutical company that develops drugs for several chronic and life-threatening diseases. “We will now begin testing the effects of their drug substances in our unique model. The company is world-leading in drug development, so this recognition is significant for us,” says Inficure Bio’s CEO, Sofia Mayans.